期刊文献+

人附睾蛋白4与溶血磷脂酸联合检测对子宫内膜癌的临床诊断价值分析 被引量:3

Clinical values of combined detection of HE4 and LPA in diagnosis of endometrial carcinoma
下载PDF
导出
摘要 目的探讨血清人附睾蛋白4(HE4)和溶血磷脂酸(LPA)联合检测对子宫内膜癌的诊断价值。方法采用酶联免疫吸附法和电化学发光法分别检测子宫内膜癌患者、子宫内膜异位症患者、功能失调性子宫出血患者及健康者血清HE4和血浆LPA水平,比较各研究组HE4和LPA水平及阳性率,分析HE4、LPA单项及联合检测对子宫内膜癌的诊断效能。结果子宫内膜癌组HE4、LPA水平较其他3组明显升高(P<0.05);HE4单项检测诊断子宫内膜癌的灵敏度为48.58%、特异度为95.74%,LPA单项检测的诊断灵敏度为68.96%、特异度为87.23%,二者联合检测的诊断灵敏度为75.86%、特异度为87.23%,联合检测的诊断灵敏度较LPA、HE4单项增高(P<0.05)。结论 HE4和LPA联合检测对子宫内膜癌的诊断效能优于二者单项检测。 Objective To investigate the diagnostic value of combined detection of human epididymis proteins 4 (HE4)and lysophosphatidic acid LPA for endometrial carcinoma.Methods Enzyme linked immunosorbent assay and electrochemiluminescence were used for the detection of serum HE4 and plasma LPA in healthy subjects and three patient groups,including endometrial cancer,endometriosis uterine and dysfunctional uterine bleeding.The lev-els and positive rates of serum HE4 and plasma LPA were compared between the four groups.The diagnostic per-formance of HE4,LPA and combined detection in endometrial cancer were analyzed.Results The levels of HE4 and LPA in endometrial cancer patients were obviously higher than the other three groups (P&lt;0.05).The diagnostic sensitivities of HE4 and LPA in diagnosis of endometrial cancer were 48.58% and 68.96% respectively,and the spe-cificities were 95.74% and 87.23% respectively.The specificity of combined detection of HE4 and LPA was 87.23%,and the sensitivity was 75.86%,which was higher than individual detection (P&lt;0.05).Conclusion The diagnostic value of combined detection of serum HE4 and LPA could be higher than individual detection for the diag-nosis of endometrial cancer.
出处 《检验医学与临床》 CAS 2014年第4期445-447,共3页 Laboratory Medicine and Clinic
关键词 子宫内膜癌 人附睾蛋白4 溶血磷脂酸 联合检测 诊断效能 human EPIDIDYMIS PROTEIN 4 endometrial cancer lysophosphatidic acid combined detec-tion diagnostic performance
  • 相关文献

参考文献11

  • 1Sorosky JI. Endometrial cancer[J]. Obstet Gynecol, 2008, 111(1) :186-187.
  • 2Drapkin R,von Horsten HH,Lin Y,et al. Human epidid- ymis protein4 (HE4)is a secreted glycoprotein that is overexpressed by serous and dometrioid ovarian carcino- mas[J].Cancer Res,2005,65(6) :2162-2169.
  • 3Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action:critical new players in breast cancer initiation and progression[J]. Br J Cancer, 2010, 102 (6) : 941-946.
  • 4Bese T,Barbaros M,Baykara E,et al. Comparison of total plasma lysophosphatidic acid and serum CA125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer[J]. Gynecol Oncol, 2010,21 (4) :248-254.
  • 5Andersen MR,Golf BA,Lowe KA,et al. Use of a Symp- tom Index, CA125, and HE4 to predict ovarian cancer[J]. Gynecol Oncol, 2010,116 (3) : 378-383.
  • 6Hellstrm I, Raycraft J, Hayden-Ledbetter M, et al. The HE4(WFDC2) protein is a biomarker for ovarian carei- noma[J]. Cancer Res, 2003,63 (13) : 3695-3700.
  • 7Powell JL, Hill KA, Shiro BC, et al. Preoperative serum CA-125 levels in treating endometrial cancer[J]. J Reprod Med,2005,50(8) :585-590.
  • 8吴飞,周慧芹,崔满华.联合检测CA125与HE4在子宫内膜癌诊断中的价值[J].中国妇幼保健,2011,26(10):1559-1561. 被引量:13
  • 9Moore RG, Brown AK, Miller MC, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometri- oid adenocarcinoma of the uterus [J].Gynecol Oncol, 2008,110(2) :196-201.
  • 10Wang FQ, Ariztia EV, Boyd LR, etal. Lysophosphatidic acid(LPA) effects on endometrial carcinoma in vitro pro- liferation,invasion, and matrix metalloproteinase activity [J]. Gynecol Oncol, 2010,117 ( 1 ): 88-95.

二级参考文献17

  • 1Moore RG, Brown AK, Miller MC et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenneatcinoma of the uterus [J]. Gyneeol Oncol, 2008 , 110 (2) : 196.
  • 2Martina Montagnana, Giuseppe Lippi, Orazio Ruzzenente et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass [ J ] . Journal of Clinical Laboratory Analysis, 2009, 23 : 331.
  • 3Lu KH, Patterson AP, Wang Let al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis [J]. Clin Cancer Res, 2004, 10 (10) : 3291.
  • 4Ginath S, Menczer J, Fintsi Yet al. Tissue and serum CA125 expression in endometrial cancer[ J ]. Int J Gynecol Cancer,2002,12 (4) :372.
  • 5Powell JL, Hill KA, Shiro BC et al. Preoperative serum CA - 125 levels in treating endometrial cancer [ J] . J Reprod Med, 2005, 50 (8) : 585.
  • 6Li J, Dowdy S, Tipton T et al. HE4 as a biomarker for ovarian and endometrial cancer management [J] . Expert Rev Mol Diagn, 2009, 9 (6) : 555.
  • 7Sorosky JI. Endometrial cancer. Obstet Gynecol, 2008, 112 : 186 - 187.
  • 8Panupinthu N, Lee HY, Mills GB. Lysophosphatidie acid pro- duction and action: critical new players in breast cancer initia- tion and progression. Br J Cancer, 2010, 102:941 - 946.
  • 9Bese T, Barbaros M, Baykara E, et al. Comparison of total plasma lysophosphatidic acid and serum CAlxs as a tumor marker in the diagnosis and follow - up of patients with epi- thelial ovarian cancer. J Gynecol Oncol, 2010, 21: 248- 254.
  • 10Tsujino M, Fujii M, Okabe K, et al. Differential expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in human colon cancer cells. Virchows Arch, 2010, 457: 669-676.

共引文献18

同被引文献21

  • 1Anton C, Carvalho FM, Oliveira EI, et al. A comparison of CA125, HEA, risk ovarian malignancy algorithm (ROMA) , and risk malignancy index (RMI) for the classification of ovarian masses[J]. Clinics ( Sao Paulo), 2012,67 ( 5 ) :437 - 441.
  • 2Sandri MT, Bottari F, Franchi D, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outeome[ J ]. Gynecol Oncol, 2013,128 (2) :233 - 238.
  • 3Karlsen MA, Sandhu N, Hogdall C, et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass[J]. Gynecol Oncol, 2012,127(2) :379 -383.
  • 4Havrilesky/d, Whitehead CM, Rubatt JM, et al. Evaluation of biomar- ker panels for early stage ovarian cancer detection and monitoring for disease recurrence [ J ]. Gvnecol Oncol. 2008.110 ( 3 ):374 - 382.
  • 5Lenhard M, Stieber P, Hertlein L, et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses[ J]. Clin Chem Lab Med, 2011,49(12) :2081 -2088.
  • 6Langmar Z, Nmeth M, Vlesk6 G, et at. HFA - a novel promising ser- um marker in the diagnosis of ovarian carcinoma [ J ]. Eur J Gynaecol Oncol, 2011,32(6) :605 -610.
  • 7Moore RG, MeMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[ J]. Gynecol 0ncol,2009,112 ( 1 ) :40 - 46.
  • 8黄薇,朱慧莉.妇科恶性肿瘤患者的激素治疗问题[J].中国实用妇科与产科杂志,2008,24(7):507-509. 被引量:4
  • 9张辉,韩波.检测CA125、CA153和CA72-4对卵巢癌诊断及疗效观察的临床价值[J].临床和实验医学杂志,2010,9(8):568-569. 被引量:17
  • 10王岚.血清CA125检测对子宫内膜癌的临床价值[J].海南医学,2012,23(1):119-123. 被引量:7

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部